A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis

British Journal of Cancer

Volumn 108, Issue 1, 2013, Pages 21-24

  Santoro, A ^a   Simonelli, M ^a   Rodriguez Lope, C ^b   Zucali, P ^a   Camacho, L H ^c   Granito, A ^d   Senzer, N ^e   Rimassa, L ^a   Abbadessa, G ^f   Schwartz, B ^f   Lamar, M ^f   Savage, R E ^f   Bruix, J ^b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF BARCELONA   (Spain)

^c ST LUKE S EPISCOPAL HOSPITAL   (United States)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e Mary Crowley Cancer Research Centers   (United States)

^f ARQULE INC   (United States)

Author keywords

Hepatocellular carcinoma; liver cirrhosis; liver function; MET inhibitor; tivantinib

Indexed keywords

BILIRUBIN; TIVANTINIB;

ADULT; AGED; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BILIRUBIN BLOOD LEVEL; CANCER GROWTH; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL ARTICLE; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FUNCTION; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PERIPHERAL EDEMA; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SCORING SYSTEM; SEPTIC SHOCK; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-MET; PYRROLIDINONES; QUINOLINES; RETREATMENT;

EID: 84872600260     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.556     Document Type: Article

References (24)

1. Bagai R, Fan W, Ma PC (2010) ARQ-197, an oral small molecule inhibitor of c-Met for the treatment of solid tumors. IDrugs 13(6): 404-414.
2. Bathala MS, Nakai D, Murai T, Pickersgill F, Zahir H, Tokui T (2012) Absorption, distribution, metabolism, and excretion of 14C-labeled tivantinib (ARQ 197) in healthy male subjects. 103rd Annual Meeting of the American Association for Cancer Research. 31 Mar-4 Apr 2012; Chicago, IL. Abstract 747.
3. Boix L, Rosa JL, Ventura F, Castells A, Bruix J, Rodes J, Bartrons R (1994) c-met mRNA overexpression in human hepatocellular carcinoma. Hepatology 19(1): 88-91.
4. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42(5): 1208-1236.
5. Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53(3): 1020-1022.
6. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1): 25-34.
7. CTCAE (2006) Common Terminology Criteria for Adverse Events version 3.0 http://ctep.cancer.gov/protocoldevelopment/electronic-applications/docs/ctcaev3. pdf.
8. EASL-EORTC (2012) European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 56(4): 908-943.
9. Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379(9822): 1245-1255.
10. Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso JR, Boix L, Sala M, Varela M, Llovet JM, Bru C, Bruix J (2008) Diagnosis of hepatic nodules 20mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47(1): 97-104.
11. Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS (2006) Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 116(6): 1582-1595.
12. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4): 378-390.
13. Munshi N, Jeay S, Li Y, Chen CR, France DS, Ashwell MA, Hill J, Moussa MM, Leggett DS, Li CJ (2010) ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 9(6): 1544-1553.
14. NCCN (2011) National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology, Hepatobiliary Cancers, version 2.1012 http://www.nccn.org.
15. Previdi S, Abbadessa G, Dalo F, France DS, Broggini M (2012) Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown. Mol Cancer Ther 11(1): 214-223.
16. Rosen LS, Senzer N, Mekhail T, Ganapathi R, Chai F, Savage RE, Waghorne C, Abbadessa G, Schwartz B, Dreicer R (2011) A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res 17(24): 7754-7764.
17. Salvi A, Arici B, Portolani N, Giulini SM, De Petro G, Barlati S (2007) In vitro c-met inhibition by antisense RNA and plasmid-based RNAi down-modulates migration and invasion of hepatocellular carcinoma cells. Int J Oncol 31(2): 451-460.
18. Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, Van Vlieberghe H, Trojan J, Kolligs FT, Weiss A, Miles S, Gasbarrini A, Lencioni M, Cicalese L, Sherman M, Gridelli C, Buggish P, Gerken G, Schmid RM, Boni C, Personeni N, Hassoun Z, Abbadessa G, Schwartz B, Von Roemeling R, Lamar ME, Chen Y, Porta C (2012) Efficacy and safety of tivantinib as second-line therapy for advanced hepatocellular carcinoma: a phase 2, randomized, placebo-controlled study. Lancet Oncol; e-pub ahead of print 19 November 2012; doi: 10.1016/S1470-2045(12)70490-4.
19. Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, Chen Y, Costa DB, Gerber DE, Orlov S, Ramlau R, Arthur S, Gorbachevsky I, Schwartz B, Schiller JH (2011) Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 29(24): 3307-3315.
20. Verbeeck RK (2008) Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64(12): 1147-1161.
21. Wang R, Ferrell LD, Faouzi S, Maher JJ, Bishop JM (2001) Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol 153(5): 1023-1034.
22. Xie B, Xing R, Chen P, Gou Y, Li S, Xiao J, Dong J (2010) Down-regulation of c-Met expression inhibits human HCC cells growth and invasion by RNA interference. J Surg Res 162(2): 231-238.
23. Yap TA, Olmos D, Brunetto AT, Tunariu N, Barriuso J, Riisnaes R, Pope L, Clark J, Futreal A, Germuska M, Collins D, deSouza NM, Leach MO, Savage RE, Waghorne C, Chai F, Garmey E, Schwartz B, Kaye SB, de Bono JS (2011) Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 29(10): 1271-1279.
24. Zahir H, Kastrissios H, Carothers T, Jansen M, Mendel J, Savage R, Abbadessa G, Chai F, Schwartz B, Miller R, Tokui T (2012) Exposure-response relationship to assess the risk of neutropenia in patients with hepatocellular carcinoma (HCC) treated with tivantinib. Ann Oncol 23(suppl 9): ix244-ix245Abstract 738P.